Literature DB >> 14972657

Substance P microinjected into the periaqueductal gray matter induces antinociception and is released following morphine administration.

Annika Rosén1, Yu-Xuan Zhang, Irene Lund, Thomas Lundeberg, Long-Chuan Yu.   

Abstract

The aims of the present study were to investigate, in rats, the behavioral effects of substance P (SP) microinjected into the ventrolateral periaqueductal gray (PAG) and the effects of the neurokinin 1 (NK-1) receptor antagonist [d-Arg1, d-Trp7, 9, Leu11]-substance P (Spantide). The effect of morphine administration on the release of SP in the ventrolateral PAG was also investigated using microdialysis in awake rats. SP microinjected into the ventrolateral part of the PAG induced significant increases in the hindpaw withdrawal latencies (HWLs) to thermal and mechanical stimulation as an antinociceptive response. The NK-1 receptor antagonist blocked these effects but exhibited no antinociceptive effect alone. Subcutaneous administration of morphine increased basal SP-like immunoreactivity (SP-LI) release in the microdialysate obtained from the ventrolateral PAG of freely moving rats. Our results demonstrate that SP injected into the ventrolateral PAG induces an antinociceptive effect via activation of NK-1 receptors. Morphine administered systemically induces the release of SP in the ventrolateral PAG. We suggest that an increased release of SP in the PAG may contribute to opioid antinociception.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972657     DOI: 10.1016/j.brainres.2003.11.060

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

2.  Characteristics of substance P transport across the blood-brain barrier.

Authors:  Arvind K Chappa; Kenneth L Audus; Susan M Lunte
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.200

3.  Placebo effects on human mu-opioid activity during pain.

Authors:  Tor D Wager; David J Scott; Jon-Kar Zubieta
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

4.  Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats.

Authors:  Gabriel S Bassi; Ana C Broiz; Margarete Z Gomes; Marcus L Brandão
Journal:  Psychopharmacology (Berl)       Date:  2008-12-18       Impact factor: 4.530

5.  The superior colliculus of the camel: a neuronal-specific nuclear protein (NeuN) and neuropeptide study.

Authors:  E P K Mensah-Brown; L J Garey
Journal:  J Anat       Date:  2006-02       Impact factor: 2.610

6.  Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway.

Authors:  Geoffrey M Drew; Benjamin K Lau; Christopher W Vaughan
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

7.  An NK1 receptor antagonist microinjected into the periaqueductal gray blocks lateral hypothalamic-induced antinociception in rats.

Authors:  Janean E Holden; Julie A Pizzi; Younhee Jeong
Journal:  Neurosci Lett       Date:  2009-02-07       Impact factor: 3.046

8.  Effects of neurokinin-1 receptor agonism and antagonism in the rostral ventromedial medulla of rats with acute or persistent inflammatory nociception.

Authors:  M V Hamity; S R White; D L Hammond
Journal:  Neuroscience       Date:  2009-11-03       Impact factor: 3.590

9.  Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain.

Authors:  Katsumichi Takeda; Mai Muramatsu; Toshiyuki Chikuma; Takeshi Kato
Journal:  J Mol Neurosci       Date:  2009-08-04       Impact factor: 3.444

Review 10.  Neuronal pathways linking substance P to drug addiction and stress.

Authors:  K G Commons
Journal:  Brain Res       Date:  2009-11-11       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.